Bioventus price to free cash flow BVS

Market value divided by free cash flow over the last twelve months, since 2022.

Today, Oct 23, 2026: 13.3×
5-year median: 25.8×
Against its 5-year history: 28th; percentile: 0 is its lowest day, 100 its highest
5-year range: 7.1× to 216×
Peer median: 20.0×

Bioventus' price to free cash flow is 13.3× as of Oct 23, 2026.

That is below its 5-year median of 25.8×, lower than on 72% of days in the last 5 years.

Over that time it ranged from 7.1× in May 2026 to 216× in Jul 2024.

The median for 10 medical instruments and supplies stocks of a similar size is 20.0×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	13.3×	7.1×	13.6×
2025	11.5×	11.0×	29.8×
2024	29.7×	29.7×	216×
2023	38.6×	29.0×	45.4×
2022	61.9×	42.7×	68.9×

Against its peers

Companies in Medical - Instruments & Supplies nearest Bioventus' size, closest first, today.

Company	Price to free cash flow
BVSBioventus	13.3×
CDRECadre	16.4×
STAAStaar Surgical	n/m
IRMDIradimed	43.7×
EYENational Vision	30.1×
LMATLemaitre Vascular	26.2×
INSPInspire Medical Systems	17.6×
MOVMovado	9.8×
UFPTUFP Technologies	n/m
MDXGMimedx	n/m
TCMDTactile Systems Technology	20.0×
Peer median	20.0×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Bioventus

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.